{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,12]],"date-time":"2026-10-12T18:55:33Z","timestamp":1791831333267,"version":"4.3.4"},"reference-count":26,"publisher":"Japanese Society for Pediatric Endocrinology","issue":"1","content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Clin Pediatr Endocrinol"],"published-print":{"date-parts":[[2025]]},"DOI":"10.1297\/cpe.2024-0069","type":"journal-article","created":{"date-parts":[[2024,11,23]],"date-time":"2024-11-23T17:11:17Z","timestamp":1732381877000},"page":"13-18","source":"Crossref","is-referenced-by-count":3,"title":["Newborn screening for congenital adrenal hyperplasia: Utility of liquid          chromatography with tandem mass spectrometry as a secondary test"],"prefix":"10.1297","volume":"34","author":[{"given":"Toshihiro","family":"Tajima","sequence":"first","affiliation":[{"name":"Department of Pediatrics, Jichi Children\u2019s Hospital Medical Center Tochigi,              Shimotsuke, Japan"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"125","reference":[{"key":"1","unstructured":"1. Tajima,              T, Fujikura,                K, Fukushi,                M, Hotsubo,                T,                Mitsuhashi,              Y. Neonatal            screening for congenital adrenal hyperplasia in Japan. Pediatr            Endocrinol Rev          2012;10(Suppl 1):            72\u20138."},{"key":"2","doi-asserted-by":"crossref","unstructured":"2. Tajima,              T, Fukushi,                M. Neonatal            mass screening for 21-hydroxylase deficiency. Clin Pediatr            Endocrinol          2016;25: 1\u20138.","DOI":"10.1297\/cpe.25.1"},{"key":"3","doi-asserted-by":"crossref","unstructured":"3. Tsuji,              A, Konishi,                K,              Hasegawa, S,                Anazawa, A,                Onishi, T,                Ono, M,              et al. Newborn screening for congenital            adrenal hyperplasia in Tokyo, Japan from 1989 to 2013: a retrospective population-based            study. BMC Pediatr          2015;15: 209.","DOI":"10.1186\/s12887-015-0529-y"},{"key":"4","doi-asserted-by":"crossref","unstructured":"4. Lacey,              JM, Minutti,                CZ, Magera,                MJ,                Tauscher,              AL, Casetta,                B, McCann,                M, et al.            Improved specificity of newborn screening for congenital adrenal            hyperplasia by second-tier steroid profiling using tandem mass            spectrometry. Clin Chem          2004;50: 621\u20135.","DOI":"10.1373\/clinchem.2003.027193"},{"key":"5","doi-asserted-by":"crossref","unstructured":"5. Janzen,              N, Peter,                M, Sander,                S,                Steuerwald,              U, Terhardt,                M,              Holtkamp, U,              et al. Newborn screening for congenital            adrenal hyperplasia: additional steroid profile using liquid chromatography-tandem mass            spectrometry. J Clin Endocrinol Metab          2007;92: 2581\u20139.","DOI":"10.1210\/jc.2006-2890"},{"key":"6","doi-asserted-by":"crossref","unstructured":"6. Matern,              D,              Tortorelli,            S, Oglesbee,                D,              Gavrilov, D,                Rinaldo,            P. Reduction of            the false-positive rate in newborn screening by implementation of MS\/MS-based            second-tier tests: the Mayo Clinic experience (2004-2007). J            Inherit Metab Dis          2007;30: 585\u201392.","DOI":"10.1007\/s10545-007-0691-y"},{"key":"7","doi-asserted-by":"crossref","unstructured":"7. Schwarz,              E, Liu,                A, Randall,                H, Haslip,                C, Keune,                F, Murray,                M, et al.            Use of steroid profiling by UPLC-MS\/MS as a second tier test in newborn            screening for congenital adrenal hyperplasia: the Utah experience.            Pediatr Res          2009;66: 230\u20135.","DOI":"10.1203\/PDR.0b013e3181aa3777"},{"key":"8","doi-asserted-by":"crossref","unstructured":"8. Dhillon,              K, Ho,                T, Rich,                P, Xu,                D, Lorey,                F, She,                J, et al.            An automated method on analysis of blood steroids using liquid            chromatography tandem mass spectrometry: application to population screening for            congenital adrenal hyperplasia in newborns. Clin Chim            Acta          2011;412: 2076\u201384.","DOI":"10.1016\/j.cca.2011.07.009"},{"key":"9","doi-asserted-by":"crossref","unstructured":"9. Seo,              JY, Park,                HD, Kim,                JW, Oh,                HJ, Yang,                JS, Chang,                YS, et al.            Steroid profiling for congenital adrenal hyperplasia by tandem mass            spectrometry as a second-tier test reduces follow-up burdens in a tertiary care            hospital: a retrospective and prospective evaluation. J Perinat            Med          2014;42:            121\u20137.","DOI":"10.1515\/jpm-2013-0154"},{"key":"10","doi-asserted-by":"crossref","unstructured":"10. Bialk,              ER, Lasarev,                MR, Held,                PK.            Wisconsin\u2019s Screening Algorithm for the Identification of Newborns with            Congenital Adrenal Hyperplasia. Int J Neonatal Screen          2019;5: 33.","DOI":"10.3390\/ijns5030033"},{"key":"11","doi-asserted-by":"crossref","unstructured":"11. Lai,              F,              Srinivasan,            S, Wiley,                V. Evaluation            of a Two-Tier Screening Pathway for Congenital Adrenal Hyperplasia in the New South            Wales Newborn Screening Programme. Int J Neonatal            Screen          2020;6: 63.","DOI":"10.3390\/ijns6030063"},{"key":"12","doi-asserted-by":"crossref","unstructured":"12. de                Hora, MR,                Heather,            NL, Patel,                T,                Bresnahan,              LG, Webster,                D, Hofman,                PL.            Implementing steroid profiling by liquid chromatography-tandem mass            spectrometry improves newborn screening for congenital adrenal hyperplasia in New            Zealand. Clin Endocrinol (Oxf)          2021;94: 904\u201312.","DOI":"10.1111\/cen.14422"},{"key":"13","doi-asserted-by":"crossref","unstructured":"13. Stroek,              K, Ruiter,                A, van der                Linde, A,                Ackermans,              M, Bouva,                MJ, Engel,                H, et al.            Second-tier testing for 21-hydroxylase deficiency in the Netherlands: A            newborn screening Pilot study. J Clin Endocrinol Metab          2021;106: e4487\u201396.","DOI":"10.1210\/clinem\/dgab464"},{"key":"14","doi-asserted-by":"crossref","unstructured":"14. Cavarzere,                P, Camilot,                M, Palma,                L,              Lauriola, S,                Gaudino, R,                Vincenzi,            M, et al.            Twenty years of neonatal screening for congenital adrenal hyperplasia in            North-Eastern Italy: Role of liquid chromatography-tandem mass spectrometry as a            second-tier test. Horm Res Paediatr          2022;95: 255\u201363.","DOI":"10.1159\/000524170"},{"key":"15","doi-asserted-by":"crossref","unstructured":"15. Lind-Holst,                M,                B\u00e6kvad-Hansen,              M, Berglund,                A, Cohen,                AS,                Melgaard,            L, Skogstrand,                K, et al.            Neonatal screening for congenital adrenal hyperplasia in Denmark: 10 yr            of experience. Horm Res Paediatr          2022;95: 35\u201342.","DOI":"10.1159\/000522230"},{"key":"16","doi-asserted-by":"publisher","unstructured":"16. Zhan,              X, Han,                L, Qiu,                W, Gu,                X, Guo,                J, Chang,                S, et al.            Steroid profile in dried blood spots by liquid chromatography tandem mass            spectrometry: Application to newborn screening for congenital adrenal hyperplasia in            China. Steroids          2022;185: 109056.","DOI":"10.1016\/j.steroids.2022.109056"},{"key":"17","doi-asserted-by":"crossref","unstructured":"17. de                Hora, MR,                Heather,            NL, Webster,                DR, Albert,                BB, Hofman,                PL.            Evaluation of a new laboratory protocol for newborn screening for            congenital adrenal hyperplasia in New Zealand. Int J Neonatal            Screen          2022;8: 56.","DOI":"10.3390\/ijns8040056"},{"key":"18","unstructured":"18. Fujikura,                K,                Yamagishi,              T, Tagami,                Y, Hanai,                J,                Takahashi,              H, Sasaki,                T, et al.            Second-tier test of neonatal screening for congenital adrenal hyperplasia            using Liquid chromatography-tandem mass spectrometry. Nihon Masu            Sukuriningu Gakkai Shi          2013;23: 85\u201392(in            Japanese)."},{"key":"19","unstructured":"19. Kanda,              K, Onizuka,                M, Kawano,                M, Sawada,                H. Evaluation            of second tier on congenital adrenal hyperplasia by tandem mass            spectrometry. J Prev Med (Wilmington)          2018;501: 42\u20135(in            Japanese)."},{"key":"20","unstructured":"20. Yamagishi,                T,              Fujikura, K,                Abe, S,                Tezuka, M,                Nomachi, Y,                Hosomi, N,              et al. Steroid profiling for CAH screening            using LC-MS\/MS. Nihon Masu Sukuriningu Gakkai Shi          2016;26: 43\u201350(in            Japanese)."},{"key":"21","unstructured":"21. Isobe,              M, Iwasaki,                N, Fukue,                A, Saito,                Y. 5 year            results of newborn screening for congenital adrenal hyperplasia introduced second-tier            test using LC-MS\/MS in Saitama city. Nihon Masu Sukuriningu            Gakkai Shi          2020;33: 9\u201317(in            Japanese)."},{"key":"22","doi-asserted-by":"crossref","unstructured":"22. Watanabe,                K,                Tsuji-Hosokawa,              A, Hashimoto,                A, Konishi,                K, Ishige,                N, Yajima,                H, et al.            The high prevalence of 21deoxycortisol, (androstenedione +            17\u03b1-hydroxyprogesterone)\/cortisol, and 11-deoxycortisol\/17\u03b1-hydroxyprogesterone for            newborn screening of 21-hydroxylase deficiency. J Clin            Endocrinol Metab          2022;107: 3341\u201352.","DOI":"10.1210\/clinem\/dgac521"},{"key":"23","doi-asserted-by":"crossref","unstructured":"23. Gau,              M, Konishi,                K,              Takasawa, K,                Nakagawa,            R,                Tsuji-Hosokawa,              A, Hashimoto,                A, et al.            The progression of salt-wasting and the body weight change during the            first 2\u00a0weeks of life in classical 21-hydroxylase deficiency patients.            Clin Endocrinol (Oxf)          2021;94: 229\u201336.","DOI":"10.1111\/cen.14347"},{"key":"24","doi-asserted-by":"crossref","unstructured":"24. Zetterstr\u00f6m,                RH,                Karlsson,            L, Falhammar,                H, Lajic,                S,                Nordenstr\u00f6m,              A. Update on            the Swedish newborn screening for congenital adrenal hyperplasia due to 21-hydroxylase            deficiency. Int J Neonatal Screen          2020;6: 71.","DOI":"10.3390\/ijns6030071"},{"key":"25","doi-asserted-by":"crossref","unstructured":"25. Speiser,                PW, Arlt,                W, Auchus,                RJ, Baskin,                LS, Conway,                GS, Merke,                DP, et al.            Congenital adrenal hyperplasia due to steroid 21-hydroxylase deficiency:            an endocrine society clinical practice guideline. J Clin            Endocrinol Metab          2018;103: 4043\u201388.","DOI":"10.1210\/jc.2018-01865"},{"key":"26","doi-asserted-by":"crossref","unstructured":"26. Ishii,              T, Kashimada,                K, Amano,                N,              Takasawa, K,                Nakamura-Utsunomiya,              A, Yatsuga,                S, et al.            Clinical guidelines for the diagnosis and treatment of 21-hydroxylase            deficiency (2021 revision). Clin Pediatr Endocrinol          2022;31: 116\u201343.","DOI":"10.1297\/cpe.2022-0009"}],"container-title":["Clinical Pediatric Endocrinology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.jstage.jst.go.jp\/article\/cpe\/34\/1\/34_2024-0069\/_pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,1,10]],"date-time":"2025-01-10T23:26:49Z","timestamp":1736551609000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.jstage.jst.go.jp\/article\/cpe\/34\/1\/34_2024-0069\/_article"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025]]},"references-count":26,"journal-issue":{"issue":"1","published-print":{"date-parts":[[2025]]}},"URL":"https:\/\/doi.org\/10.1297\/cpe.2024-0069","relation":{},"ISSN":["0918-5739","1347-7358"],"issn-type":[{"value":"0918-5739","type":"print"},{"value":"1347-7358","type":"electronic"}],"subject":[],"published":{"date-parts":[[2025]]},"article-number":"2024-0069"}}